Vanguard Global Advisers
RCKT icon

Vanguard Global Advisers’s Rocket Pharmaceuticals RCKT Stock Holding History

Vanguard Global Advisers’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$105K Hold
30,623
– – ﹤0.01% 2760
2026
Q1 		$110K Buy
+30,623
New +$122K ﹤0.01% 2691

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Global Advisers's RCKT Position: Q2 2026 in Review

Vanguard Global Advisers held its Rocket Pharmaceuticals (RCKT) position steady in Q2 2026 at 30,623 shares worth $105K. The position accounts for ﹤0.01% of the portfolio, ranked #2760.

Vanguard Global Advisers first reported a position in RCKT in Q1 2026 and has held it in 2 quarters since. The position peaked at $110K in Q1 2026. 176 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Vanguard Global Advisers held 30,623 shares of Rocket Pharmaceuticals worth $105K as of Q2 2026.
  • Vanguard Global Advisers left its Rocket Pharmaceuticals share count unchanged in Q2 2026.
  • Rocket Pharmaceuticals made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2760 holding.
  • Vanguard Global Advisers first reported a position in Rocket Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's Rocket Pharmaceuticals position peaked at $110K in Q1 2026.
  • 176 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.